Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery

We propose to evaluate the benefit in 2-year iDFS and safety of adding capecitabine to pembrolizumab in post-operative phase of pembrolizumab-containing treatment, in the subgroup of localized TNBC patients with residual disease.

An external cohort with patients treated with pembrolizumab as part of standard care after surgery, for localized TNBC without pCR after NAC, and with similar eligibility criteria, will be registered in an ambispective way, allowing comparisons between the experimental arm and this external cohort. All the centers involved in the study will participate in the registration of the needed information concerning this cohort.

• CRITERIA FOR EXPERIMENTAL ARM :

Inclusion criteria

(for experimental arm):

Patients eligible for this study must meet ALL of the following criteria:

• Patient must have signed a written informed consent prior to any trial specific procedures. When the patient is physically unable to give their written consent, a trusted person of their choice, independent from the investigator or the sponsor, can confirm in writing the patient's consent;
• Subject ≥18 years of age on day of signing informed consent form (ICF);
• Histologically proven TNBC defined as follows:

• HER2 negativity (ASCO/CAP criteria)
• AND less than 10% of cells stained by immunohistochemistry (IHC) for ER and PgR;
• TNBC patients previously treated by standard neoadjuvant chemotherapy with a minimum of 6 cycles of immunochemotherapy containing pembrolizumab, per standard of care (and pembrolizumab label) and anthracyclines and/or taxanes (with/without carboplatin). Other drugs may be acceptable following discussion with the sponsor (with the exclusion of capecitabine);
• Complete resection of the breast tumor(s) (and of any invaded lymph node);
• No complete pathological response, defined as RCB Class I, II or III (per local assessment);
• Available representative formalin-fixed paraffin-embedded (FFPE) tumor block from surgery specimen with its histological report;
• Eastern Cooperative Oncology Group (ECOG) Performance Status <2;
• Adequate organ and bone marrow function. All screening lab tests should be performed within 28 days before inclusion;
• Resolution to at least grade 1 of all acute toxicities from previous therapies including immune-related toxicity due to pembrolizumab, except alopecia and grade 2 immune-related endocrinopathies controlled by hormone replacement which are allowed;
• Minimal/maximal period for prior treatments (i.e. minimal delay from last dose of prior treatment to C1D1): breast surgery (the wound must have healed prior to C1D1) ≥2 weeks (maximum 10 weeks); last pembrolizumab injection ≥3 weeks;
• Women of child-bearing potential must have a negative serum pregnancy test within 7 days before C1D1;
• Women of child-bearing potential and male patients must agree to use 1 effective form of contraception from the time of the negative pregnancy test up to 6 months after the last dose of study drugs;
• Patient should be able and willing to comply with study visits and procedures as per protocol;
• Patients must be affiliated to a Social Security System (or equivalent).

Non-inclusion criteria (for experimental arm):

Patients eligible for this study must not meet ANY of the following criteria:

• Radiological or clinical evidence of metastatic disease documented by imaging or clinical examination performed during screening period;
• Has received capecitabine or other ICI than pembrolizumab in the NAC regimen;
• Has a known additional malignancy, excepted skin basal cell carcinoma, squamous cell carcinoma of the skin, or in situ cervical cancer or previously treated malignancy with no evidence of disease for ≥2 years;
• Presents a contraindication to continue pembrolizumab treatment as per respective SmPC including known hypersensitivity;
• Previous immune-related adverse event of any grade due to pembrolizumab that led to permanent discontinuation of pembrolizumab;
• Presents a contraindication to capecitabine treatment as per SmPC (See EMA website for most recent edition of SmPC);
• Complete DPD (Dihydropyrimidine Dehydrogenase) deficiency (a systematic screening of DPD deficiency must be performed);
• Patient with active infection ;
• Patients with history of uncontrolled or symptomatic cardiac disease ;
• Patients having received brivudine within 4 weeks prior to inclusion;
• Require the use of one of the following forbidden treatments during the study treatment period:

• Any investigational anticancer therapy other than the protocol specified treatment;
• Any concurrent chemotherapy, immunotherapy, biologic for cancer treatment, other than the ones stated in the protocol;
• Pregnant women or women who are breast-feeding;
• Patients unwilling or unable to comply with the medical follow-up required by the trial because of geographic, familial, social, or psychological reasons;
• Persons deprived of their liberty or under protective custody or guardianship;
• Participation in another therapeutic trial within the 30 days prior to randomization.

• CRITERIA FOR STANDARD OF CARE TREATED EXTERNAL COHORT

Inclusion criteria

(for standard of care treated external cohort) :

Patients eligible for this cohort must meet ALL of the following criteria:

• Patient information prior to study entry and non-opposition to data collection
• Subject ≥18 years of age ;
• Histologically proven TNBC defined as follows:

• HER2 negativity (ASCO/CAP criteria)
• AND less than 10% of cells stained by immunohistochemistry (IHC) for ER and PgR;
• TNBC patients previously treated by standard neoadjuvant chemotherapy with a minimum of 6 cycles of immunochemotherapy containing pembrolizumab, per standard of care (and pembrolizumab label) and anthracyclines and/or taxanes (with/without carboplatin). Other drugs may be acceptable following discussion with the sponsor (with the exclusion of capecitabine);
• Complete resection of the breast tumor(s) (and of any invaded lymph node);
• No complete pathological response, defined as RCB Class I, II or III (per local assessment);
• Patient should have received at least one injection of pembrolizumab as post-surgery treatment (concomitantly or after radiotherapy).

Non-exclusion criteria (for standard of care treated external cohort) :

Patients eligible for this study must not meet ANY of the following criteria:

• Radiological or clinical evidence of metastatic disease documented by imaging or clinical examination after surgery.
• Has received capecitabine or other ICI than pembrolizumab in the NAC regimen;
• Has a known additional malignancy, excepted skin basal cell carcinoma, squamous cell carcinoma of the skin, or in situ cervical cancer or previously treated malignancy with no evidence of disease for ≥2 years;
• Any investigational anticancer therapy (chemotherapy, immunotherapy, biologic for cancer treatment) other than pembrolizumab only as adjuvant treatment.